MS Exercise: What Improves Walking, and Where tDCS Fits

Aerobic exercise can improve walking speed, walking endurance, and balance in people with mild-to-moderate multiple sclerosis (MS). The harder question—how much, how hard, and for whom—still lacks a settled answer. Current evidence also draws a useful boundary: exercise programs aimed at the motor system improve motor outcomes more consistently than they improve fatigue, cardiorespiratory fitness, or cognition.

That boundary matters when choosing a rehabilitation plan. Walking training is a sensible foundation for mobility goals. Anodal transcranial direct current stimulation (tDCS) may add a small motor benefit when a clinic delivers it immediately before physiotherapy. Neither intervention should be sold as a universal treatment for every MS symptom.

What aerobic training reliably improves

A 2021 systematic review and meta-analysis of aerobic training included 43 studies and 1,070 participants with MS. Compared with control conditions, aerobic training produced statistically significant benefits for balance (P=.02), gait speed (P=.02), and walking endurance (P=.03). Those are patient-centered outcomes: getting across a room faster, walking farther, and reducing instability are practical gains.

The analysis did not establish a universal dose. Its subgroup analysis found that continuous walking-based programs had a larger gait-speed signal than interval methods (χ²=9.36, P=.002). This fits a plausible rehabilitation principle: practicing walking may improve walking. But the comparison was post hoc, not a pre-specified head-to-head trial. It generates a practical hypothesis; it does not prove that intervals are inferior for every person with MS.

A 2024 meta-analysis of exercise programs in MS also found improvements in mobility and balance across exercise types. That independent result makes the motor finding more credible than any single training format or research group could make it.

One reported balance standardized mean difference in the aerobic-training review requires caution. A value that large would be unusual in rehabilitation research and may partly reflect pooling very different balance measures, rather than one uniform clinical effect. The published evidence supports better balance overall; it does not justify treating an unusually large pooled statistic as a promise of dramatic improvement for an individual.

Fatigue and fitness are not settled wins

The same aerobic-training meta-analysis found within-group improvement in cardiorespiratory fitness and fatigue, but neither outcome showed a statistically significant advantage over control conditions. For cardiorespiratory fitness, the between-group estimate was SMD 0.14 (P=.19). A participant can improve during a program while the program still fails to outperform the comparison group. That distinction matters, especially when fatigue fluctuates and control groups receive attention, advice, or other care.

Underdosing is one possible explanation. A 2022 study of higher-intensity aerobic exercise, targeting at least 60% of VO₂peak, reported improved fatigue and walking. It supports testing whether many earlier programs used too little intensity to move these outcomes. It does not settle the question: this was one study, not a replicated dose-comparison program designed to prove that intensity explains the pooled null results.

Fatigue itself is not one clean target. A 2024 study in progressive MS linked fatigue impact with physical and neurobehavioral factors. Pooling people whose fatigue has different drivers can dilute a treatment effect. Exercise may help some people substantially, but current between-group evidence does not show that aerobic training reliably beats alternatives for fatigue across the broader MS population.

Use aerobic exercise for mobility and general health, then measure your own fatigue response. If fatigue worsens after sessions or fails to improve despite a well-designed program, changing the dose, timing, cooling strategy, equipment, or treatment plan is more rational than simply adding grit.

Who may benefit, and where walking stops being practical

Training response varies. A 2026 study of predictors of motor-training response found that lower baseline cardiorespiratory fitness, greater functional impairment, higher fatigue, and slower gait predicted greater improvement. This does not prove that more disabled people always respond better, but it argues against assuming that only minimally impaired patients are worth enrolling in structured exercise.

The controlled evidence for aerobic training and tDCS mainly covers mild-to-moderate disability, broadly Expanded Disability Status Scale (EDSS) scores up to about 4 to 6. People with more substantial walking disability need individualized programming rather than a copied walking plan. A 2024 feasibility trial found that adaptive-equipment HIIT was achievable in people with MS and walking disability. A 2026 pilot randomized trial in people with severe fatigue and walking impairment found that peak-velocity interval training may match or exceed moderate-intensity continuous walking for fatigue and walking outcomes. These studies challenge the idea that continuous walking suits every disability level, but neither provides definitive efficacy evidence for EDSS above 6.

Access need not require constant clinic attendance. A 2026 randomized trial of hybrid and remote rehabilitation tested an eight-week program in 44 people with EDSS scores from 0 to 4, with gait speed as the primary outcome. It showed that remote-supported exercise models can deliver functional rehabilitation without every session occurring in a clinic. That is relevant for exercise delivery, not a license to move every rehabilitation technology into the living room.

tDCS can amplify physiotherapy, modestly

tDCS uses a weak electrical current applied through scalp electrodes. In MS rehabilitation, the best-supported use is narrow: supervised anodal stimulation over primary motor cortex before physiotherapy.

A 2024 double-blind randomized trial enrolled 40 people with MS, with average EDSS around 3.5. Participants received 12 sessions of anodal tDCS—2 mA for 20 minutes over primary motor cortex—immediately before 60 minutes of individualized physiotherapy, or sham stimulation before the same therapy. At seven weeks, the active group had statistically significant advantages in Berg Balance Scale scores and 10-meter walk speed. The advantages persisted, with marginal further improvement, at six months.

The result is encouraging but modest. Twenty percent of participants had dropped out by the six-month assessment, which reduces follow-up precision. The balance change approached but may not have clearly exceeded the roughly 3.5-point minimal clinically important difference reported for the Berg Balance Scale in MS. Retention also does not prove that tDCS reorganized the cortex; sustained motor learning from physiotherapy could explain the pattern.

A 2023 systematic review and meta-analysis of randomized tDCS trials independently supports benefits for gait and balance. It also supports restraint: neither the 2024 trial nor the review found a between-group benefit for fatigue. The trial also found no advantage for falls frequency or quality of life. More current through the same circuit does not automatically mean more rehabilitation. A 2025 randomized study combining transcranial and trans-spinal stimulation with robot-assisted gait training found mixed results, with no clear added benefit from the spinal stimulation.

Do not treat tDCS as a home biohack

The positive tDCS trial used in-person clinical supervision, impedance monitoring, verified electrode placement, and immediate physiotherapy. The proposed mechanism—temporarily increasing corticospinal excitability so practice can shape motor pathways—remains biologically plausible but unproven in MS-specific neurophysiology studies.

A 2025 trial of remotely supervised tDCS with virtual-reality telerehabilitation found that the model was feasible and reported some functional benefits. Feasibility is not proof that unsupervised home stimulation is safe or equivalent to clinic delivery. MS lesions vary in location and burden, individual response to stimulation is unpredictable, and current evidence does not validate DIY tDCS for MS.

The practical verdict

Build MS exercise around the outcome you want to improve. For walking, endurance, and balance, aerobic training has the strongest evidence, and continuous walking is a reasonable starting format for ambulatory people. For fatigue and cardiorespiratory fitness, use an individualized plan and track results rather than assuming pooled evidence guarantees a benefit. Exercise therapy can improve physical function without improving cognition, as a 2023 randomized trial in early MS showed, so cognitive symptoms need their own assessment and treatment plan.

For someone already in formal physiotherapy, supervised anodal tDCS may provide a small additional gain in gait and balance. It belongs in a clinical rehabilitation program, not beside the blender and the supplements. The evidence supports targeted motor rehabilitation; it does not support a one-tool answer to MS.